SMT201600156B - Trattamento dell’osteoartrite - Google Patents

Trattamento dell’osteoartrite

Info

Publication number
SMT201600156B
SMT201600156B SM201600156T SM201600156T SMT201600156B SM T201600156 B SMT201600156 B SM T201600156B SM 201600156 T SM201600156 T SM 201600156T SM 201600156 T SM201600156 T SM 201600156T SM T201600156 B SMT201600156 B SM T201600156B
Authority
SM
San Marino
Prior art keywords
osteoartritis
treatment
Prior art date
Application number
SM201600156T
Other languages
English (en)
Italian (it)
Inventor
John Allan Hamilton
Andrew David Cook
Original Assignee
Univ Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42286786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600156(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Melbourne filed Critical Univ Melbourne
Publication of SMT201600156B publication Critical patent/SMT201600156B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Glass Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Polarising Elements (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SM201600156T 2008-12-22 2016-06-01 Trattamento dell’osteoartrite SMT201600156B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967908P 2008-12-22 2008-12-22
US16448609P 2009-03-30 2009-03-30
PCT/AU2009/001672 WO2010071924A1 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment

Publications (1)

Publication Number Publication Date
SMT201600156B true SMT201600156B (it) 2016-08-31

Family

ID=42286786

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600156T SMT201600156B (it) 2008-12-22 2016-06-01 Trattamento dell’osteoartrite

Country Status (19)

Country Link
US (4) US9243061B2 (https=)
EP (2) EP3056217B1 (https=)
JP (3) JP5727379B2 (https=)
KR (2) KR101898982B1 (https=)
CN (2) CN102271705A (https=)
AU (1) AU2009329814B2 (https=)
BR (1) BRPI0918356B1 (https=)
CA (1) CA2746827C (https=)
CY (1) CY1117698T1 (https=)
DK (1) DK2376121T4 (https=)
ES (2) ES2572368T5 (https=)
HK (1) HK1226938A1 (https=)
HR (1) HRP20160577T4 (https=)
HU (1) HUE028615T2 (https=)
PL (1) PL2376121T5 (https=)
RU (2) RU2712273C2 (https=)
SI (2) SI2376121T1 (https=)
SM (1) SMT201600156B (https=)
WO (1) WO2010071924A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2630969C2 (ru) 2008-12-22 2017-09-15 Де Юниверсити Оф Мельбурн Лечение боли
EP3056217B1 (en) * 2008-12-22 2021-06-30 The University of Melbourne Osteoarthritis treatment
EP3345923A1 (en) 2012-09-20 2018-07-11 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody
DE102013222200A1 (de) * 2013-10-31 2015-08-27 Osram Opto Semiconductors Gmbh Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements
IL301622A (en) * 2017-08-14 2023-05-01 Zynerba Pharmaceuticals Inc Methods for treating degenerative joint disease with cannabidiol gel through the skin
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU630496B2 (en) 1989-07-14 1992-10-29 Schering Corporation Antagonists of gm-csf derived from the carboxyl terminus
WO1991002063A1 (en) 1989-08-11 1991-02-21 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2149881A1 (en) 1992-11-19 1994-05-26 Paul T. Jubinsky Antibodies for gm-csf receptor and uses thereof
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
EP1442132A2 (en) * 2001-10-26 2004-08-04 Novartis AG Methods for the treatment of osteoarthritis and compositions thereof
US7381801B2 (en) 2002-02-13 2008-06-03 Ludwig Institute For Cancer Research Chimerized GM-CSF antibodies
US20040241755A1 (en) * 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
BRPI0506679A (pt) 2004-02-11 2007-05-15 Warner Lambert Co métodos de tratar osteoartrite com antagonistas de il-6
CN1960758B (zh) * 2004-03-31 2014-10-22 中外制药株式会社 关节炎的治疗剂或预防剂
EP1593690B1 (en) 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
EP1782074A2 (en) * 2004-08-18 2007-05-09 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Biomarkers for osteoarthritis
US20060040258A1 (en) 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
EP2468774A3 (en) 2005-04-18 2013-01-02 Amgen Research (Munich) GmbH Antibody neutralizers of human granulocyte macrophage colony stimulating factor
EP3620171B1 (en) * 2005-05-18 2022-04-20 MorphoSys AG Anti-gm-csf antibodies and uses therefor
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
EA200801166A1 (ru) * 2005-12-01 2008-12-30 Домантис Лимитед Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
CA2641169C (en) * 2006-02-08 2017-05-02 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
PL1999152T3 (pl) 2006-03-27 2013-05-31 Medimmune Ltd Element wiążący receptor GM-CSF
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
US20080206241A1 (en) * 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
WO2008080134A2 (en) * 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
WO2008141391A1 (en) 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009042854A1 (en) * 2007-09-26 2009-04-02 Musculoskeletal Research Llc Ion-channel regulator compositions and methods of using same
EP2217626A4 (en) 2007-11-12 2011-06-22 Crc For Asthma And Airways Ltd EPITOP FOR NEUTRALIZING ANTIBODIES
PE20091420A1 (es) 2007-11-13 2009-10-17 Evec Inc ANTICUERPOS MONOCLONALES ANTI hGM-CSF
US20100040630A1 (en) 2008-03-24 2010-02-18 Aake Elden Methods and compositions for treating bone loss
NZ588850A (en) 2008-04-28 2012-12-21 Kalobios Pharmaceuticals Inc Antibodies to granulocyte-macrophage colony-stimulating factor
RU2630969C2 (ru) 2008-12-22 2017-09-15 Де Юниверсити Оф Мельбурн Лечение боли
EP3056217B1 (en) * 2008-12-22 2021-06-30 The University of Melbourne Osteoarthritis treatment
CN102459340A (zh) 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体

Also Published As

Publication number Publication date
BRPI0918356B1 (pt) 2022-03-08
HRP20160577T4 (hr) 2021-08-20
AU2009329814B2 (en) 2015-06-18
SI2376121T2 (sl) 2021-11-30
RU2712273C2 (ru) 2020-01-28
AU2009329814A1 (en) 2010-07-01
EP2376121A1 (en) 2011-10-19
JP5727379B2 (ja) 2015-06-03
CY1117698T1 (el) 2017-05-17
ES2572368T5 (es) 2021-12-16
JP2012512815A (ja) 2012-06-07
EP2376121B2 (en) 2021-06-09
KR20170128630A (ko) 2017-11-22
PL2376121T3 (pl) 2016-12-30
CN106397591A (zh) 2017-02-15
US9243061B2 (en) 2016-01-26
US20200247895A1 (en) 2020-08-06
EP2376121B1 (en) 2016-03-09
CA2746827C (en) 2018-01-23
EP3056217A1 (en) 2016-08-17
US20160185868A1 (en) 2016-06-30
HRP20160577T1 (hr) 2016-07-29
RU2016102339A (ru) 2018-11-21
ES2886063T3 (es) 2021-12-16
KR20110128273A (ko) 2011-11-29
US20120003234A1 (en) 2012-01-05
JP2015143233A (ja) 2015-08-06
PL2376121T5 (pl) 2021-09-27
JP2017200933A (ja) 2017-11-09
HK1226938A1 (en) 2017-10-13
KR101898982B1 (ko) 2018-09-14
DK2376121T4 (da) 2021-08-16
DK2376121T3 (en) 2016-05-30
HUE028615T2 (en) 2016-12-28
EP2376121A4 (en) 2013-04-03
JP6458086B2 (ja) 2019-01-23
KR101799264B1 (ko) 2017-11-20
BRPI0918356A2 (pt) 2020-10-06
SI2376121T1 (sl) 2016-07-29
US20180066062A1 (en) 2018-03-08
RU2011127334A (ru) 2013-01-27
EP3056217B1 (en) 2021-06-30
RU2016102339A3 (https=) 2019-07-29
WO2010071924A1 (en) 2010-07-01
CA2746827A1 (en) 2010-07-01
CN102271705A (zh) 2011-12-07
ES2572368T3 (es) 2016-05-31

Similar Documents

Publication Publication Date Title
BR112012001325A2 (pt) tratamento de distúrbios do fígado com inibidaores de pi3k
PL2621523T3 (pl) Sposoby leczenia choroby autoimmunologicznej z zastosowaniem biokompatybilnych bioabsorbowalnych nanosfer
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
BRPI0916931A2 (pt) agentes terapêuticos
DK2222272T3 (da) Behandling af luftvejssygdom
PT2448582T (pt) Compostos e composições terapêuticas
PL2506850T3 (pl) Sposoby podawania terapii pirfenidonem
BRPI0910854A2 (pt) métodos de tratamento
DK2330887T3 (da) Behandlingsindretning
PL2435825T3 (pl) Sposoby leczenia chorób
GB0818074D0 (en) Treatment of biofilms
SMT201600156B (it) Trattamento dell’osteoartrite
ME03508B (me) Kombinovana terapija za liječenje dijabetesa
SMT201600332B (it) Composizioni e metodi per l’aumento dell’attivitàtelomerasica
EP2349335A4 (en) LEVETIRACETAM IMMUNOASSAYS
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
DK2252317T3 (da) Behandling af makuladegeneration
EP2367606A4 (en) BONDING BEHAVIOR SHOWING TOY
BRPI0907954A2 (pt) Tratamento de hipertensão com 25-hidroxivitamina d3
BRPI0917210A2 (pt) exoterma controlada de formulações de cianocrilato
EP3381471C0 (en) PAIN TREATMENT
DK2501381T3 (da) Behandling af atrieflimmer
CU23884B1 (es) Derivados de dibenzotiazepina
BRPI0915761A2 (pt) composto de heterociclila para tratamento de doença cardiovascular
DK2173197T3 (da) Fremgangsmåde